{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T05:09:48Z","timestamp":1782364188553,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s40744-024-00658-1","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T14:01:44Z","timestamp":1710770504000},"page":"599-615","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE"],"prefix":"10.1007","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct02629159","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6630-1477","authenticated-orcid":false,"given":"Roy","family":"Fleischmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3561-5932","authenticated-orcid":false,"given":"Filip","family":"Van den Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Bessette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanna","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara K.","family":"Penn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"McDearmon-Blondell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Mysler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,18]]},"reference":[{"key":"658_CR1","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1080\/14397595.2020.1782049","volume":"30","author":"Y Tanaka","year":"2020","unstructured":"Tanaka Y. A review of upadacitinib in rheumatoid arthritis. Mod Rheumatol. 2020;30:779\u201387.","journal-title":"Mod Rheumatol"},{"key":"658_CR2","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1002\/art.41384","volume":"72","author":"R van Vollenhoven","year":"2020","unstructured":"van Vollenhoven R, Takeuchi T, Pangan AL, et al. Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator-controlled trial. Arthritis Rheumatol. 2020;72:1607\u201320.","journal-title":"Arthritis Rheumatol"},{"key":"658_CR3","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685\u201399.","journal-title":"Ann Rheum Dis"},{"key":"658_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82:3\u201318.","journal-title":"Ann Rheum Dis"},{"key":"658_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.755844","volume":"12","author":"Z Wang","year":"2021","unstructured":"Wang Z, Huang J, Xie D, He D, Lu A, Liang C. Toward overcoming treatment failure in rheumatoid arthritis. Front Immunol. 2021;12:755844.","journal-title":"Front Immunol"},{"issue":"2","key":"658_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003196","volume":"9","author":"MA Messelink","year":"2023","unstructured":"Messelink MA, den Broeder AA, Marinelli FE, et al. What is the best target in a treat-to-target strategy in rheumatoid arthritis? Results from a systematic review and meta-regression analysis. RMD Open. 2023;9(2):e003196.","journal-title":"RMD Open"},{"key":"658_CR7","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","volume":"391","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase\u00a03 trial. Lancet. 2018;391:2513\u201324.","journal-title":"Lancet"},{"key":"658_CR8","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","volume":"393","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase\u00a03 study. Lancet. 2019;393:2303\u201311.","journal-title":"Lancet"},{"key":"658_CR9","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","volume":"383","author":"A Rubbert-Roth","year":"2020","unstructured":"Rubbert-Roth A, Enejosa J, Pangan AL, et al. Trial of upadacitinib or abatacept in rheumatoid arthritis. N Engl J Med. 2020;383:1511\u201321.","journal-title":"N Engl J Med"},{"key":"658_CR10","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1136\/annrheumdis-2019-216656","volume":"79","author":"A Kerschbaumer","year":"2020","unstructured":"Kerschbaumer A, Sepriano A, Smolen JS, et al. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2020;79:744\u201359.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 6","key":"658_CR11","doi-asserted-by":"publisher","first-page":"vi16","DOI":"10.1093\/rheumatology\/kes281","volume":"51","author":"VP Bykerk","year":"2012","unstructured":"Bykerk VP, Massarotti EM. The new ACR\/EULAR remission criteria: rationale for developing new criteria for remission. Rheumatology (Oxford). 2012;51(Suppl 6):vi16-20.","journal-title":"Rheumatology (Oxford)"},{"key":"658_CR12","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/acr.24042","volume":"71","author":"BR England","year":"2019","unstructured":"England BR, Tiong BK, Bergman MJ, et al. 2019 Update of the American College of Rheumatology recommended rheumatoid arthritis disease activity measures. Arthritis Care Res (Hoboken). 2019;71:1540\u201355.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"658_CR13","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73:924\u201339.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"658_CR14","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","volume":"381","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase\u00a03 trial. Lancet. 2013;381:451\u201360.","journal-title":"Lancet"},{"key":"658_CR15","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374:1243\u201352.","journal-title":"N Engl J Med"},{"key":"658_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/jama.2019.9055","volume":"322","author":"MC Genovese","year":"2019","unstructured":"Genovese MC, Kalunian K, Gottenberg JE, et al. Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial. JAMA. 2019;322:315\u201325.","journal-title":"JAMA"},{"key":"658_CR17","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1136\/annrheumdis-2019-215764","volume":"78","author":"RM Fleischmann","year":"2019","unstructured":"Fleischmann RM, Genovese MC, Enejosa JV, et al. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48\u00a0weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis. 2019;78:1454\u201362.","journal-title":"Ann Rheum Dis"},{"key":"658_CR18","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1136\/annrheumdis-2020-218510","volume":"80","author":"SB Cohen","year":"2021","unstructured":"Cohen SB, van Vollenhoven RF, Winthrop KL, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase\u00a0III clinical programme. Ann Rheum Dis. 2021;80:304\u201311.","journal-title":"Ann Rheum Dis"},{"key":"658_CR19","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","volume":"391","author":"GR Burmester","year":"2018","unstructured":"Burmester GR, Kremer JM, Van den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase\u00a03 trial. Lancet. 2018;391:2503\u201312.","journal-title":"Lancet"},{"key":"658_CR20","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/art.41032","volume":"71","author":"R Fleischmann","year":"2019","unstructured":"Fleischmann R, Pangan AL, Song IH, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase\u00a0III, double-blind, randomized controlled trial. Arthritis Rheumatol. 2019;71:1788\u2013800.","journal-title":"Arthritis Rheumatol"},{"key":"658_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","volume":"2","author":"JM Parmentier","year":"2018","unstructured":"Parmentier JM, Voss J, Graff C, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018;2:23.","journal-title":"BMC Rheumatol"},{"key":"658_CR22","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1136\/annrheumdis-2020-218412","volume":"80","author":"RM Fleischmann","year":"2021","unstructured":"Fleischmann RM, Blanco R, Hall S, et al. Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis. Ann Rheum Dis. 2021;80:432\u20139.","journal-title":"Ann Rheum Dis"},{"key":"658_CR23","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1093\/rheumatology\/keac477","volume":"62","author":"E Mysler","year":"2023","unstructured":"Mysler E, Tanaka Y, Kavanaugh A, et al. Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE. Rheumatology (Oxford). 2023;62:1804\u201313.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"658_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-002012","volume":"8","author":"R Fleischmann","year":"2022","unstructured":"Fleischmann R, Mysler E, Bessette L, et al. Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3\u00a0years from the SELECT-COMPARE study. RMD Open. 2022;8(1):e002012.","journal-title":"RMD Open"},{"key":"658_CR25","first-page":"1401","volume":"34","author":"T Woodworth","year":"2007","unstructured":"Woodworth T, Furst DE, Alten R, et al. Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0. J Rheumatol. 2007;34:1401\u201314.","journal-title":"J Rheumatol"},{"issue":"1","key":"658_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002735","volume":"9","author":"GR Burmester","year":"2023","unstructured":"Burmester GR, Cohen SB, Winthrop KL, et al. Safety profile of upadacitinib over 15,000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023;9(1):e002735.","journal-title":"RMD Open"},{"key":"658_CR27","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s12325-019-01145-8","volume":"37","author":"GR Burmester","year":"2020","unstructured":"Burmester GR, Gordon KB, Rosenbaum JT, et al. Long-term safety of adalimumab in 29,967 adult patients from global clinical trials across multiple indications: an updated analysis. Adv Ther. 2020;37:364\u201380.","journal-title":"Adv Ther"},{"key":"658_CR28","doi-asserted-by":"publisher","first-page":"1759720x2110026","DOI":"10.1177\/1759720X211002682","volume":"13","author":"A Migliore","year":"2021","unstructured":"Migliore A, Pompilio G, Integlia D, Zhuo J, Alemao E. Cycling of tumor necrosis factor inhibitors versus switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibitors: a Bayesian network meta-analysis. Ther Adv Musculoskelet Dis. 2021;13:1759720x211002682.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"658_CR29","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1136\/annrheumdis-2018-214529","volume":"78","author":"Y Tanaka","year":"2019","unstructured":"Tanaka Y, Fautrel B, Keystone EC, et al. Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and\/or study design: phase\u00a0III data in patients with rheumatoid arthritis. Ann Rheum Dis. 2019;78:890\u20138.","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00658-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-024-00658-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00658-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T15:30:45Z","timestamp":1716391845000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-024-00658-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["658"],"URL":"https:\/\/doi.org\/10.1007\/s40744-024-00658-1","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,18]]},"assertion":[{"value":"15 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Roy Fleischmann has received consulting fees and\/or grant\/research support from AbbVie, Amgen, BI, Biosplice, BMS, DREN Bio, Flexion, Galapagos, Galvani, Genentech, Gilead, GSK, Horizon, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi-Aventis, Selecta, Teva, UCB, Viela, Vorso, and Vyne. Ricardo Blanco has received grant\/research support from AbbVie, MSD, and Roche; and consulting fees\/participated in speaker\u2019s bureau from AbbVie, BMS, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer, and Roche. Filip Van den Bosch has received speaker and\/or consulting fees from AbbVie, Amgen, BMS, Galapagos, Janssen, Lilly, Merck, Novartis, Sanofi, and UCB. Louis Bessette has received speaking fees, consulting fees, and grant\/research support from AbbVie, Amgen, BMS, Celgene, Lilly, Fresenius Kabi, Gilead, Janssen, Merck, Novartis, Organon, Pfizer, Roche, Sanofi-Aventis, Teva, and UCB. Yanna Song, Sara K. Penn, Erin McDearmon-Blondell, Nasser Khan, and Kelly Chan are employees of AbbVie and may hold stock or options. Eduardo Mysler has received speaking fees, consulting fees, and grant\/research support from AbbVie, Amgen, AstraZeneca, BMS, Hi-Bio, Janssen, Lilly, Novartis, Pfizer, Roche, Sandoz, and Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study is being conducted according to the International Council for Harmonization guidelines, local regulations and guidelines governing clinical study conduct, and the Declaration of Helsinki. All patients provided written informed consent, and the study protocol and consent forms were approved by an institutional review board or independent ethics committee at each study site. Approval was received from the master ethics committee, the Advarra Institutional Review Board (Pro00034396).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}